Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQConsumer DiscretionaryPackaging & ContainersSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for YHGJ yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
stabilize leadership after chairman resignation | A supporting condition in YUNHONG GREEN CTI LTD's published investment case. The stated target is appoint permanent chairman and reduce management volatility. | Under Pressure | no permanent chairman appointed within next 4 quarters | No permanent chairman appointed vs target within 4 quarters Chairman Yubao Li resigned in Feb 2026 without a named successor. No subsequent news confirms a permanent appointment. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative turnaround, meaning the thesis depends on a loss-making business improving its results. The long-term thesis is in a watch state: operating losses have narrowed, but recent financial performance is weak, company quality has fallen, and profitability remains negative.
The evidence describes YHGJ as cheap versus peers, but also shows a negative expectations gap, meaning expectations appear demanding relative to the model’s view. Confidence in that valuation signal is low, and the business is still loss-making, so the apparent discount does not resolve the underlying execution risk.
Near term, the risk of another earnings miss is elevated, with a 63% estimated miss probability, and revenue declined to $3.9 million in 2026-Q2 after earlier growth. Operating losses have narrowed from $983,000 in 2025-Q3 to $320,000 in 2026-Q2, but profitability remains negative. Management’s new M&A priority has no reported financial impact yet, while recent sales progress is limited.
Over the next few quarters, the thesis hinges on whether management can stabilize revenue and keep reducing operating losses. Consumer Discretionary sector momentum may help if TRS, MYE, and KRT continue to report strong results and guidance, while weaker results could remove that support. A material slowdown in GDP growth from 2.1% to below 2% would be an added risk for this growth-sensitive sector.
For a 1-3 year view, YHGJ remains a high-risk, loss-making turnaround with some progress on costs but unresolved revenue weakness. The thesis depends on sustained improvement in sales and profitability, alongside execution on the newly stated M&A priority. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
reduce losses and improve free cash flow yield |
| A primary condition in YUNHONG GREEN CTI LTD's published investment case. The stated target is free cash flow yield improves toward positive territory. |
| Broken |
| free cash flow yield remains below -20% next year |
Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
achieve at least 15% revenue growth | A primary condition in YUNHONG GREEN CTI LTD's published investment case. The stated target is >=15% YoY. | Intact | YoY revenue growth falls below 15% next year | Revenue growth: -28.53% FY2026-Q2; GAAP. Published target: >=15% YoY. Target period is not explicitly aligned with this observation. Aug 7, 2026-28.532161 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.